Retatrutide is a new-generation peptide designed for advanced metabolic health, weight management, and fitness performance. As a triple hormone receptor agonist, Retatrutide acts on GLP-1, GIP, and glucagon receptors, offering significantly greater efficacy than traditional weight-loss peptides. It has attracted strong attention in the field of obesity treatment, type 2 diabetes, and clinical research, making it one of the most promising therapeutic peptides on the market.
| Product Name | Retatrutide Peptide |
| Shelf Life | 2 Years |
| Form | Peptide |
| Indication | Weight Loss |
| Dosage | 1mg~12mg/week |
| Active Ingredient | Retatrutide |
| Storage Conditions | Store At 2-25°C |
| Packaging | 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial, 40mg/vial |
Retatrutide is primarily applied in the clinical management of obesity and type 2 diabetes, addressing unmet needs for patients with these interconnected conditions.
1. Obesity Treatment
Its mechanism targets three key receptors—GIPR (glucose-dependent insulinotropic polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor), and GCGR (glucagon receptor)—to drive weight loss at the metabolic level: it enhances fat breakdown, boosts energy metabolism, and increases basal metabolic rate, rather than relying solely on appetite suppression.
2. Type 2 Diabetes Management
As an adjunct to diet and exercise, Retatrutide is particularly beneficial for patients with type 2 diabetes who have poor glycemic control or concurrent obesity.
Its dual glucose-lowering actions include: Activating GLP-1R to stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying (reducing postprandial blood sugar spikes); Enhancing insulin sensitivity via GIPR activation, amplifying glycemic control.
For high value products, please select air shipping and express delivery for safety.
